AUR-AFKB-TTM1-A-1-1-R-A742-41
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.360
- PROTEIN_SECRETION+0.350
- OXIDATIVE_PHOSPHORYLATION+0.340
- DNA_REPAIR+0.310
- TGF_BETA_SIGNALING+0.230
- MYC_TARGETS_V2+0.180
- ANDROGEN_RESPONSE+0.140
- E2F_TARGETS+0.120
- ADIPOGENESIS+0.080
- G2M_CHECKPOINT+0.030
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.540
- ANGIOGENESIS-0.540
- INTERFERON_GAMMA_RESPONSE-0.530
- INFLAMMATORY_RESPONSE-0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- INTERFERON_ALPHA_RESPONSE-0.500
- IL6_JAK_STAT3_SIGNALING-0.490
- HEDGEHOG_SIGNALING-0.430
- COMPLEMENT-0.410
- TNFA_SIGNALING_VIA_NFKB-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0395 | Med | Medulloblastoma | 0.896 |
| 2 | BS_VA5T4KAA | medulloblastoma | — | 0.894 |
| 3 | BS_K74PZET7 | Med | Medulloblastoma | 0.893 |
| 4 | SRR8943005 | — | — | 0.891 |
| 5 | BS_9NJHQE9F | medulloblastoma | — | 0.890 |
| 6 | BS_H4B5Y6S0 | medulloblastoma | — | 0.888 |
| 7 | SRR5088890 | — | — | 0.887 |
| 8 | TCGA-B6-A0IC-01A-11R-A034-07 | — | B | 0.887 |
| 9 | BS_CHDGRYHJ | medulloblastoma | — | 0.885 |
| 10 | SRR25617882 | — | B | 0.885 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.340 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.120 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.030 | Inavolisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |